Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891566920> ?p ?o ?g. }
- W2891566920 endingPage "836" @default.
- W2891566920 startingPage "827" @default.
- W2891566920 abstract "Background The clinical effects of roflumilast, a selective phosphodiesterase-4 inhibitor, are well established, but little is known about the anti-inflammatory mechanisms underlying the drug's efficacy. The aim of the ROflumilast Biopsy European Research Trial (ROBERT) was to assess the anti-inflammatory effects of roflumilast on bronchial mucosal inflammation in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and chronic bronchitis. Methods ROBERT was a randomised, double-blind, placebo-controlled trial done at 18 sites in five countries. Eligible patients were aged 40–80 years, had COPD, and had had a chronic productive cough for 3 months in each of the two previous years. Patients also had to have a post-bronchodilator predicted FEV1 30–80% and a post-bronchodilator FEV1/forced vital capacity ratio of 70% or less. Patients entered a 6-week run-in period before being randomly assigned (1:1) via a computerised central randomisation system to roflumilast 500 μg once daily or placebo for 16 weeks, in addition to bronchodilator therapy (inhaled corticosteroids were not permitted). Randomisation was stratified by concomitant use of long-acting β agonist. Both participants and investigators were masked to group assignment. Roflumilast and placebo were supplied as identical yellow, triangular tablets. Airway inflammation was assessed by quantification of inflammatory cells in bronchial biopsy samples and induced sputum samples. The primary endpoint was the change in the number of CD8 inflammatory cells in bronchial biopsy submucosa from randomisation to week 16 in the intention-to-treat population. Changes in cell counts of additional inflammatory markers, including eosinophils, were assessed as secondary endpoints. This trial is registered with ClinicalTrials.gov, number NCT01509677, and is closed to new participants, with follow-up completed. Findings Between Jan 4, 2012, and Feb 11, 2016, 158 patients were randomly assigned: 79 to the roflumilast group, and 79 to the placebo group. At week 16, the change in the number of CD8 cells in the bronchial submucosa did not differ significantly between the roflumilast and placebo groups (treatment ratio 1·03 [95% CI 0·82–1·30]; p=0·79). However, compared with placebo, roflumilast was associated with a significant reduction in eosinophils in bronchial biopsy samples at week 16 (treatment ratio 0·53 [95% CI 0·34–0·82]; p=0·0046). Significant reductions in both absolute (p=0·0042) and differential (p=0·0086) eosinophil cell counts in induced sputum were also noted with roflumilast compared with placebo, but peripheral blood eosinophil counts were not significantly affected. We noted no other significant effects of roflumilast on bronchial mucosal inflammatory cells. The most common (ie, occurring in >5% patients) moderate adverse events were worsening of COPD (three [4%] patients in the roflumilast group vs seven [9%] in the placebo group), cough (six [8%] vs four [5%]), diarrhoea (four [5%] vs three [4%]), and nasopharyngitis (three [4%] vs five [6%]). Severe adverse events included worsening of COPD, which occurred in four (5%) patients in the roflumilast group and two (3%) in the placebo group. No deaths occurred during the study. Serious adverse events occurred in eight (10%) patients in the roflumilast group and five (6%) in the placebo group. Interpretation 16 weeks of treatment with roflumilast did not affect the number of CD8 cells in bronchial submucosa compared with placebo. However, we noted significant reductions in eosinophil cell counts in bronchial biopsy samples and induced sputum, generating the hypothesis that the effect of roflumilast in COPD could be mediated by an effect on lung eosinophils. Funding Takeda and AstraZeneca." @default.
- W2891566920 created "2018-09-27" @default.
- W2891566920 creator A5001143355 @default.
- W2891566920 creator A5001469043 @default.
- W2891566920 creator A5007369928 @default.
- W2891566920 creator A5028265360 @default.
- W2891566920 creator A5030170755 @default.
- W2891566920 creator A5038607795 @default.
- W2891566920 creator A5040461586 @default.
- W2891566920 creator A5042617883 @default.
- W2891566920 creator A5052922462 @default.
- W2891566920 creator A5059577678 @default.
- W2891566920 creator A5072946332 @default.
- W2891566920 creator A5087999170 @default.
- W2891566920 date "2018-11-01" @default.
- W2891566920 modified "2023-10-17" @default.
- W2891566920 title "Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial" @default.
- W2891566920 cites W1544297197 @default.
- W2891566920 cites W1757801909 @default.
- W2891566920 cites W1760281680 @default.
- W2891566920 cites W1949956414 @default.
- W2891566920 cites W1977628719 @default.
- W2891566920 cites W1987881697 @default.
- W2891566920 cites W2001965102 @default.
- W2891566920 cites W2005401397 @default.
- W2891566920 cites W2026549814 @default.
- W2891566920 cites W2033380992 @default.
- W2891566920 cites W2036327819 @default.
- W2891566920 cites W2038335346 @default.
- W2891566920 cites W2078509571 @default.
- W2891566920 cites W2087251490 @default.
- W2891566920 cites W2096189541 @default.
- W2891566920 cites W2110947112 @default.
- W2891566920 cites W2113430717 @default.
- W2891566920 cites W2120702538 @default.
- W2891566920 cites W2121765574 @default.
- W2891566920 cites W2127294121 @default.
- W2891566920 cites W2131055445 @default.
- W2891566920 cites W2132850519 @default.
- W2891566920 cites W2138810941 @default.
- W2891566920 cites W2139397407 @default.
- W2891566920 cites W2141402647 @default.
- W2891566920 cites W2145466675 @default.
- W2891566920 cites W2151950207 @default.
- W2891566920 cites W2166667839 @default.
- W2891566920 cites W2169091680 @default.
- W2891566920 cites W2324038222 @default.
- W2891566920 cites W2513201803 @default.
- W2891566920 cites W2604501983 @default.
- W2891566920 cites W2613136430 @default.
- W2891566920 cites W2613360457 @default.
- W2891566920 cites W2765493231 @default.
- W2891566920 cites W2770113020 @default.
- W2891566920 cites W2805013685 @default.
- W2891566920 cites W4210349548 @default.
- W2891566920 doi "https://doi.org/10.1016/s2213-2600(18)30331-x" @default.
- W2891566920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30224319" @default.
- W2891566920 hasPublicationYear "2018" @default.
- W2891566920 type Work @default.
- W2891566920 sameAs 2891566920 @default.
- W2891566920 citedByCount "43" @default.
- W2891566920 countsByYear W28915669202018 @default.
- W2891566920 countsByYear W28915669202019 @default.
- W2891566920 countsByYear W28915669202020 @default.
- W2891566920 countsByYear W28915669202021 @default.
- W2891566920 countsByYear W28915669202022 @default.
- W2891566920 countsByYear W28915669202023 @default.
- W2891566920 crossrefType "journal-article" @default.
- W2891566920 hasAuthorship W2891566920A5001143355 @default.
- W2891566920 hasAuthorship W2891566920A5001469043 @default.
- W2891566920 hasAuthorship W2891566920A5007369928 @default.
- W2891566920 hasAuthorship W2891566920A5028265360 @default.
- W2891566920 hasAuthorship W2891566920A5030170755 @default.
- W2891566920 hasAuthorship W2891566920A5038607795 @default.
- W2891566920 hasAuthorship W2891566920A5040461586 @default.
- W2891566920 hasAuthorship W2891566920A5042617883 @default.
- W2891566920 hasAuthorship W2891566920A5052922462 @default.
- W2891566920 hasAuthorship W2891566920A5059577678 @default.
- W2891566920 hasAuthorship W2891566920A5072946332 @default.
- W2891566920 hasAuthorship W2891566920A5087999170 @default.
- W2891566920 hasConcept C126322002 @default.
- W2891566920 hasConcept C142724271 @default.
- W2891566920 hasConcept C204787440 @default.
- W2891566920 hasConcept C27081682 @default.
- W2891566920 hasConcept C2776042228 @default.
- W2891566920 hasConcept C2776301714 @default.
- W2891566920 hasConcept C2776780178 @default.
- W2891566920 hasConcept C2778926808 @default.
- W2891566920 hasConcept C2781018748 @default.
- W2891566920 hasConcept C2781069245 @default.
- W2891566920 hasConcept C2908647359 @default.
- W2891566920 hasConcept C2992694001 @default.
- W2891566920 hasConcept C71924100 @default.
- W2891566920 hasConcept C99454951 @default.
- W2891566920 hasConceptScore W2891566920C126322002 @default.
- W2891566920 hasConceptScore W2891566920C142724271 @default.
- W2891566920 hasConceptScore W2891566920C204787440 @default.
- W2891566920 hasConceptScore W2891566920C27081682 @default.